如何正确服用抗结核药物.pdfVIP

结核病与胸部肿瘤2007年第4期 323 2006，94(1 1)：1599～l603． age treated with erlotinib for advanced non-small—cell 19．Bell DW，Lynch rj，Haserlat SM，et al，Epidermal growth lung cancer．J Clin Oncol，2007，25(7)：760-766． factor receptor mutations and gene amplification in non— 26．Tsao MS，Sakurada A、Cutz JC．et a1．Erlotinib in lung small-cell lung cancer：molecular analysis of the IDEAL／ cancer—toolecular and clinical predictors of outcome．N INTACT gefitinib trials．J Clin Oneol，2005，23(31)：8081～ Engl J Med，2005，353，(2)：l33～l44．Erratum in：N engl J 8O92． Med。2006，355(16)：1746． 20．Giaccone G．EGFR point mutation confers resistance to 27．Balko JM，Potti A，Saunders C，et a1．Gene expression pat- gefitinib in a patient with non-small-cell lung cancer． terns that predict sensitivity to epidermal growth factor Nat Clin Pract Oncol，2005，2(6)：296～297． receptor tyrosine kinase inhibitors in lung cancer cell 21．Dowell JE，Minna JD．Chasing mutations in the epidernlal lines and human lung tumors．BMC Genomics，2006，7：289． growth factor in lung cancer．N Engl J Med，2005，352(8)： 28．Kimura H，Kasahara K，Kawaishi M．et a1．Detection of 830～832． epidermal growth factor receptor mutations in sernm as a 22．Hun SW，Kim TY，Jeon YK，et a1．Optimization of patient pedictior of the reponse to gefitionib in patients with selection for gefitinib in non—small cell lung cancer by non-small-cell lung cancer．Clin Cancer Res，2006，12(13)： combined analysis of epidermal growth factor receptor 39I5～3921． mutation．K—r舾 mutation．and Akt phosphorylation．Clin 29．Soh J，Toyooka S，Ace K．et a1．Usefulness of EGFR nuta． Cancer Res，2006，12(8)：2538～2544．